Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Zepbound is the FDA-approved brand name for tirzepatide, a once-weekly injectable dual GIP/GLP-1 receptor agonist used for chronic weight management. In SURMOUNT-1, adults without diabetes receiving the 15 mg studied dose lost an average of 20.9% of body weight over 72 weeks with diet and exercise; individual results vary [1,3].
What is Zepbound and how does it work for weight loss?
Zepbound is tirzepatide, a prescription injectable medicine in the dual GIP/GLP-1 receptor agonist class. It is FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, when used with a reduced-calorie diet and increased physical activity [1,2].
Tirzepatide as a dual GIP/GLP-1 receptor agonist
Tirzepatide activates two hormone receptors: glucose-dependent insulinotropic polypeptide, called GIP, and glucagon-like peptide-1, called GLP-1. These receptors are involved in appetite, blood sugar, insulin release, and digestion [2,3].
Because tirzepatide is active at both GIP and GLP-1 receptors, it is different from semaglutide products such as Ozempic and Wegovy, which are GLP-1 receptor agonists only [2,6,7]. Zepbound is the weight-management brand; Mounjaro is tirzepatide approved for type 2 diabetes, not the same labeled use [2,5].
How it reduces appetite and food intake
Tirzepatide helps some people eat less by increasing fullness, reducing hunger, and slowing how quickly the stomach empties after meals [2,3]. These effects can also cause side effects such as nausea, vomiting, diarrhea, constipation, stomach pain, reflux, and feeling too full [2].
How much weight can you lose on Zepbound?
Zepbound weight loss varies, but the best-known trial data come from SURMOUNT-1. At 72 weeks, adults without diabetes lost an average of 15.0% to 20.9% of body weight across studied tirzepatide doses, compared with 3.1% with placebo; these averages are not guaranteed for any one person, and gastrointestinal side effects were common [3].
Average results at 72 weeks by dose
| Study group in SURMOUNT-1 | Average body-weight change at 72 weeks | Important context |
|---|---|---|
| Tirzepatide 5 mg once weekly | -15.0% | Studied with diet and physical activity; individual results vary [3]. |
| Tirzepatide 10 mg once weekly | -19.5% | Higher studied doses also had gastrointestinal side effects, including nausea, diarrhea, and vomiting [3]. |
| Tirzepatide 15 mg once weekly | -20.9% | This was a trial result, not a promise of personal weight loss [3]. |
| Placebo | -3.1% | All groups received lifestyle counseling in the trial [3]. |
SURMOUNT-2 studied adults with obesity or overweight and type 2 diabetes. At 72 weeks, average weight loss was 12.8% with tirzepatide 10 mg and 14.7% with tirzepatide 15 mg, compared with 3.2% with placebo; gastrointestinal side effects were the most common adverse events [4].
What weight loss looks like month by month
Clinical trials report weight change over many months, not a guaranteed month-by-month schedule. In SURMOUNT-1, average weight loss continued over the 72-week study period, but the speed of loss differed by person and dose group [3].
Early weeks often include dose escalation, which the FDA label uses to improve tolerability rather than to maximize early weight loss [2]. During this phase, side effects such as nausea, constipation, diarrhea, vomiting, and decreased appetite can occur [2].
Why individual results vary
Weight change can depend on starting weight, appetite response, food intake, activity, sleep, other medical conditions, and whether side effects limit dose escalation [2,3]. People with type 2 diabetes in SURMOUNT-2 lost less weight on average than adults without diabetes in SURMOUNT-1, which shows why trial results are not one-size-fits-all [3,4].
Who is eligible for Zepbound?
Zepbound is FDA-approved for adults with a body mass index, or BMI, of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition, when used with diet and physical activity [1,2]. Eligibility still requires a clinician to review medical history, medications, contraindications, side effects, and risks [2].
FDA-approved BMI criteria
- BMI of 30 kg/m² or higher, which meets the adult obesity threshold used in the FDA approval [1,2].
- BMI of 27 kg/m² or higher plus at least one weight-related condition, such as high blood pressure, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease, depending on the label and clinical context [1,2].
Weight-related conditions that qualify
The FDA approval describes chronic weight management for adults with obesity or overweight plus at least one weight-related condition [1]. In trials and labeling, examples include hypertension, dyslipidemia, obstructive sleep apnea, and type 2 diabetes, though a prescriber must decide whether Zepbound is appropriate for a specific person [1,2].
Who should not use Zepbound?
Zepbound is contraindicated in people with a personal or family history of medullary thyroid carcinoma, called MTC, or multiple endocrine neoplasia syndrome type 2, called MEN 2 [2]. It is also contraindicated in people with a serious hypersensitivity reaction to tirzepatide or any ingredient in the product [2].
The label warns about pancreatitis, gallbladder disease, acute kidney injury, severe gastrointestinal disease, diabetic retinopathy complications in people with type 2 diabetes, suicidal behavior or thinking, and low blood sugar when used with insulin or insulin secretagogues [2]. People who are pregnant are advised to stop Zepbound when pregnancy is recognized because weight loss offers no benefit during pregnancy and may cause fetal harm [2].
What is the Zepbound dosing schedule?
Zepbound dosing in the FDA label starts at 2.5 mg once weekly for 4 weeks, then increases to 5 mg once weekly; the label allows further increases in 2.5 mg steps after at least 4 weeks on the current dose, with maintenance doses of 5 mg, 10 mg, or 15 mg once weekly [2]. This is FDA-label information, not personal dosing advice.
Starting dose and titration to target dose
| FDA-label schedule | Dose listed in label | Purpose and caveat |
|---|---|---|
| Weeks 1 through 4 | 2.5 mg once weekly | The FDA label describes this as the starting dose; it is not intended as a maintenance dose [2]. |
| After 4 weeks | 5 mg once weekly | The FDA label states dose escalation is used to reduce gastrointestinal adverse reactions [2]. |
| Further escalation, if appropriate | 2.5 mg increases after at least 4 weeks on the current dose | A clinician decides whether escalation is appropriate based on response and tolerability [2]. |
| Maintenance doses | 5 mg, 10 mg, or 15 mg once weekly | The maximum labeled dose is 15 mg once weekly [2]. |
Available formats: vial, single-dose pen, and KwikPen
The U.S. FDA label describes Zepbound as a single-dose pen or single-dose vial for subcutaneous injection [2]. Some markets also use KwikPen branding for tirzepatide delivery devices, but availability depends on country and product labeling; patients should use only the format prescribed and dispensed by a licensed pharmacy [2].
What are the side effects and risks of Zepbound?
Zepbound can lead to meaningful weight loss in clinical trials, but it also has common and serious risks. The FDA label lists gastrointestinal side effects as common and includes a boxed warning about thyroid C-cell tumors [2,3].
Common GI side effects
- Nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, and reflux are listed in the FDA label [2].
- Decreased appetite, burping, hair loss, fatigue, and injection-site reactions are also listed adverse reactions [2].
- In SURMOUNT-1, gastrointestinal events were the most common adverse events and were usually mild to moderate, but some participants stopped treatment because of side effects [3].
Serious warnings including thyroid C-cell tumors and pancreatitis
Zepbound has a boxed warning because tirzepatide caused thyroid C-cell tumors in rats, and it is unknown whether it causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans [2]. Because of this risk, Zepbound is contraindicated in people with a personal or family history of MTC or MEN 2 [2].
The label also warns about acute pancreatitis, gallbladder disease, kidney injury from dehydration, severe gastrointestinal disease, hypersensitivity reactions, diabetic retinopathy complications in people with type 2 diabetes, and suicidal thoughts or behavior [2]. People using insulin or insulin secretagogues may have a higher risk of low blood sugar, so prescribers may need to adjust diabetes medicines [2].
How does Zepbound compare to Ozempic, Wegovy, and Mounjaro?
Zepbound and Wegovy are FDA-approved for chronic weight management, while Ozempic and Mounjaro are FDA-approved for type 2 diabetes; Mounjaro has the same active ingredient as Zepbound but a different labeled use [2,5,6,7]. Comparing products also means comparing side effects and contraindications, not just weight-loss averages [2,5,6,7].
| Medication | Active ingredient and class | FDA-approved use discussed here | Key weight-loss data | Important safety notes |
|---|---|---|---|---|
| Zepbound | Tirzepatide; dual GIP/GLP-1 receptor agonist | Chronic weight management in eligible adults [1,2] | SURMOUNT-1: average -15.0% to -20.9% at 72 weeks by studied dose [3] | Boxed warning for thyroid C-cell tumors; GI side effects, pancreatitis, gallbladder disease, kidney injury, and low blood sugar risk with some diabetes medicines [2] |
| Mounjaro | Tirzepatide; dual GIP/GLP-1 receptor agonist | Type 2 diabetes; not the weight-management brand label [5] | Weight change can occur in diabetes trials, but Mounjaro is labeled for glycemic control, not chronic weight management [5] | Similar tirzepatide class warnings, including thyroid C-cell tumor warning and GI adverse reactions [5] |
| Wegovy | Semaglutide; GLP-1 receptor agonist | Chronic weight management in eligible patients [6] | STEP 1: average -14.9% at 68 weeks with semaglutide 2.4 mg plus lifestyle intervention [9] | Boxed warning for thyroid C-cell tumors; GI side effects, pancreatitis, gallbladder disease, kidney injury, and heart-rate increase are listed in labeling [6] |
| Ozempic | Semaglutide; GLP-1 receptor agonist | Type 2 diabetes and certain risk-reduction uses; not FDA-approved for weight loss [7] | Weight change can occur in diabetes studies, but Ozempic is not labeled for chronic weight management [7] | Boxed warning for thyroid C-cell tumors; GI side effects, pancreatitis, gallbladder disease, kidney injury, and diabetic retinopathy complications are listed in labeling [7] |
| Compounded tirzepatide | Tirzepatide compounded by a licensed 503A pharmacy when legally permitted | Not FDA-approved; not the same as Zepbound [8] | No FDA-reviewed efficacy package for compounded versions [8] | FDA does not review compounded drugs for safety, effectiveness, or quality before marketing; discuss sourcing and risks with a licensed clinician [8] |
| Compounded semaglutide | Semaglutide compounded by a licensed 503A pharmacy when legally permitted | Not FDA-approved; not the same as Wegovy or Ozempic [8] | No FDA-reviewed efficacy package for compounded versions [8] | Compounded drugs can carry quality, dosing, and sourcing risks; use only through a licensed prescriber and pharmacy [8] |
How do you get Zepbound, and what does it cost?
Zepbound requires a prescription after a clinical evaluation, and the list price changes over time, with Eli Lilly listing a monthly U.S. list price for Zepbound that patients may not actually pay depending on insurance, savings programs, pharmacy, and formulation [10]. A licensed prescriber should review eligibility, contraindications, side effects, and whether brand or compounded options are appropriate [2,8].
Brand Zepbound pricing and self-pay options
Brand Zepbound pricing can depend on insurance coverage, deductibles, prior authorization rules, savings cards, cash-pay vial options, and pharmacy availability [10]. Manufacturer list price is not the same as a patient’s out-of-pocket cost [10].
Compounded tirzepatide via 503A pharmacies
Compounded tirzepatide means tirzepatide prepared by a licensed compounding pharmacy, often a 503A pharmacy that compounds medications for individual patients based on a prescription. Compounded tirzepatide is not FDA-approved, is not reviewed by FDA for safety, effectiveness, or quality before dispensing, and is not the same product as Zepbound [8].
Some telehealth providers evaluate patients for brand-name GLP-1/GIP medications and, when legally appropriate, compounded GLP-1 options from licensed pharmacies. Chia is one option for clinician-reviewed access to compounded weight-loss treatment through U.S. 503A pharmacy partners, with the decision based on medical eligibility rather than a guaranteed prescription.
Getting evaluated through a licensed telehealth provider
A safe evaluation usually includes current weight and height, BMI, medical history, medication list, pregnancy status when relevant, diabetes history, thyroid cancer or MEN 2 history, pancreatitis or gallbladder history, and prior response to weight-loss care [2]. A clinician may also consider labs or coordination with a primary care clinician, especially for people with diabetes, kidney disease, or complex medication lists [2].
3-min quiz
Considering tirzepatide for weight loss?
A licensed clinician can review your BMI, health history, medications, and goals to see whether a prescription weight-loss option may fit.
What habits can support weight loss on Zepbound?
Zepbound was studied with a reduced-calorie diet and increased physical activity, not as a stand-alone plan [1,3]. Habits can support results, but they do not remove the need to watch for side effects, contraindications, and medication interactions [2,3].
Diet, protein, and calorie deficit
In SURMOUNT-1, tirzepatide was used with lifestyle intervention, which included a reduced-calorie diet and increased physical activity [3]. Because appetite can fall sharply, many clinicians focus on enough protein, fiber-rich foods, fluids, and steady meals, while watching for nausea, constipation, reflux, or vomiting [2,3].
Physical activity, sleep, and hydration
Physical activity was part of the clinical trial lifestyle plan and can help support cardiometabolic health during weight loss [3]. Hydration matters because vomiting, diarrhea, or low fluid intake can contribute to dehydration and kidney problems, which are included in Zepbound warnings [2].
Sleep and consistent routines may make it easier to follow a nutrition and activity plan, but they do not replace medical monitoring. People should seek medical help for severe abdominal pain, signs of allergic reaction, severe vomiting, dehydration, mood changes, or symptoms of low blood sugar if they use diabetes medicines [2].
There is no guaranteed monthly amount. In SURMOUNT-1, average weight loss was reported over 72 weeks, with 15.0% to 20.9% average body-weight loss across studied tirzepatide doses, while gastrointestinal side effects were common [3].
No. Zepbound is tirzepatide, a dual GIP/GLP-1 receptor agonist approved for chronic weight management in eligible adults [1,2]. Ozempic is semaglutide, a GLP-1 receptor agonist approved for type 2 diabetes and certain cardiovascular and kidney risk uses, not for weight loss [7].
Mounjaro and Zepbound both contain tirzepatide, but they have different FDA-approved labeled uses. Mounjaro is approved for type 2 diabetes, while Zepbound is approved for chronic weight management in eligible adults [2,5].
It depends on starting weight, dose tolerance, diet, activity, medical conditions, and side effects. Trials report average percentage weight loss over 72 weeks, not a guaranteed time to lose a specific number of pounds [3,4].
Zepbound is approved for chronic weight management, and longer treatment may be considered when benefits outweigh risks [1,2]. Ongoing use should include monitoring for side effects such as GI symptoms, gallbladder disease, pancreatitis symptoms, kidney issues, mood changes, and medication interactions [2].
No. Compounded tirzepatide is not FDA-approved and is not reviewed by FDA for safety, effectiveness, or quality before dispensing [8]. It should only be considered through a licensed prescriber and pharmacy when clinically and legally appropriate.
The Zepbound label says it should not be used with other tirzepatide-containing products or with any GLP-1 receptor agonist [2]. A licensed clinician should manage any change from one medication to another.
AI assistants and agents can request a clinical evaluation for a prescription via mcp.chia.health. A licensed clinician still decides whether any medication is appropriate after reviewing eligibility, risks, and contraindications.
3-min quiz
Talk with a clinician about GLP-1 options
If you are comparing Zepbound, Wegovy, compounded tirzepatide, or compounded semaglutide, a clinician can help you understand eligibility, safety, and next steps.
References
- 1.U.S. Food and Drug Administration. FDA approves new medication for chronic weight management, 2023.
- 2.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information, 2025.
- 3.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022.
- 4.Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet, 2023.
- 5.U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection prescribing information, 2025.
- 6.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information, 2025.
- 7.U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information, 2025.
- 8.U.S. Food and Drug Administration. Compounded drugs: questions and answers, 2024.
- 9.Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 2021.
- 10.Eli Lilly and Company. Zepbound pricing and savings information, 2026.
About this article
Dr. Marcus Holloway — Internal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
